Merrimack plans pancreatic cancer NDA for MM-398
This article was originally published in Scrip
Executive Summary
It's success at last for Merrimack Pharmaceuticals, which said MM-398 provided a statistically significant increase in overall survival for pancreatic cancer patients treated with the drug candidate and two other chemotherapy agents.